Company intelligence / Profile preview

Lunit

Seoul, South Korea

Ownership: Private
Employees: ~300
Development stage: Commercial

Overview

Lunit's AI solutions are used in over 2,500 hospitals across 48 countries. Their technology has shown success in cancer detection with higher cancer detection rates and lower recall rates compared to traditional methods. Their AI biomarker for EGFR mutation detection delivers results within five minutes[5][6].

Therapeutic areas: Oncology
Modalities: AI-powered diagnostic toolsAI biomarkers
Industry: Digital Health Medical Devices

Partnerships

AstraZenecaGuardant HealthGE HealthcarePhilipsFujiFilmCapio S:t Göran Hospital

Beyond the preview

Go deeper on Lunit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lunit.

Explore the full profile